FBLG FIBROBIOLOGICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, FIBROBIOLOGICS INC reported revenue of n/a, net income of −$4.12M and diluted EPS of −$0.66; for the fiscal year ended December 2025 revenue was n/a.
FBLG annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$16.6M, net income −$18.6M (margin n/a), EPS −$0.42
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$13.7M, net income −$11.2M (margin n/a), EPS −$0.34
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$8.89M, net income −$16.5M (margin n/a), EPS −$0.68
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$4.47M, net income −$5.12M (margin n/a), EPS −$0.18
FBLG quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$4.12M, EPS −$0.66
- Quarter ended Mar 31, 2026: revenue n/a, net income −$5.00M, EPS −$1.33
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$3.24M, EPS $4.83
- Quarter ended Sep 30, 2025: revenue n/a, net income −$5.78M, EPS −$0.13
- Quarter ended Jun 30, 2025: revenue n/a, net income −$4.66M, EPS −$2.41
- Quarter ended Mar 31, 2025: revenue n/a, net income −$4.97M, EPS −$2.71
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$3.10M, EPS −$0.09
- Quarter ended Sep 30, 2024: revenue n/a, net income −$500K, EPS −$0.01
- Quarter ended Jun 30, 2024: revenue n/a, net income $898K, EPS $0.03
- Quarter ended Mar 31, 2024: revenue n/a, net income −$8.46M, EPS −$0.27
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$9.72M, EPS −$0.34
- Quarter ended Sep 30, 2023: revenue n/a, net income −$2.19M, EPS −$0.08
- Quarter ended Jun 30, 2023: revenue n/a, net income −$2.16M, EPS −$0.08
- Quarter ended Mar 31, 2023: revenue n/a, net income −$2.42M, EPS −$0.18
FBLG cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$16.4M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$11.9M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$6.40M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$4.07M, share buybacks n/a
FBLG balance sheet
- Jun 30, 2026: cash $3.52M, total assets $7.93M, total liabilities $3.29M, shareholders' equity $4.64M
- Mar 31, 2026: cash $1.48M, total assets $5.94M, total liabilities $3.34M, shareholders' equity $2.60M
- Dec 31, 2025: cash $4.89M, total assets $9.62M, total liabilities $3.46M, shareholders' equity $6.16M
- Sep 30, 2025: cash $4.87M, total assets $8.74M, total liabilities $8.62M, shareholders' equity $125K
- Jun 30, 2025: cash $8.85M, total assets $13.9M, total liabilities $13.0M, shareholders' equity $860K
- Mar 31, 2025: cash $8.67M, total assets $11.4M, total liabilities $9.08M, shareholders' equity $2.35M
- Dec 31, 2024: cash $14.0M, total assets $16.4M, total liabilities $13.7M, shareholders' equity $2.74M
- Sep 30, 2024: cash $7.83M, total assets $10.5M, total liabilities $7.73M, shareholders' equity $2.74M
Is FBLG profitable?
No. FIBROBIOLOGICS INC lost $18.1M over the last four quarters.
What is FBLG's EPS?
Diluted earnings per share over the last four quarters were $2.71; −$0.66 in the latest quarter.